

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 11, 2015		
<u>LEXARIA CORP.</u> (Exact name of registrant as specified in its charter)		
Nevada (State or other jurisdiction of incorporation)	000-52138 (Commission File Number)	20-2000871 (IRS Employer Identification No.)
#950 – 1130 West Pender Street, Vancouver, British Columbia, Canada V6E 4A4		
Registrant's telephone number, including area code: (604) 602-1675		
(Former name or former address, if changed since last report.)		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01 Entry into a Material Definitive Agreement

On August 11, 2015, the Company signed a 35 year license agreement with PoViva Tea LLC for \$10,000.

Item 7.01 Regulation FD Disclosure.

A copy of the news release announcing the agreement is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit No.	Description
<u>10.1</u>	<u>License Agreement dated August 11, 2015</u>
<u>99.1</u>	<u>Press Release dated August 12, 2015</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 12, 2015

(Signature) Lexaria Corp.
By: “/s/ Chris Bunka”
Chris Bunka
President & CEO

LICENSE AGREEMENT

THIS AGREEMENT dated for reference 11th day of August, 2015.

AMONG:

PoViva Tea LLC with an address at 1495 Ridgeview Drive, Suite 220 Reno, Nevada 89519

(herein called "Licensor")

AND:

Lexaria Corp., a corporation registered in the State of Nevada with an address at Suite 950 - 1130 West Pender Street, Vancouver, BC V6E 4A4

(herein called "Licensee")

WHEREAS:

A. The Licensor owns controlling interest in, and has further developed and refined certain patent pending processes designed to deliver certain molecules such as THC, CBD, Nicotine, NSAID's and others within the presence of lipids according to United States and foreign patents and patent applications listed in Exhibit A, (the "**Patents**") which are hereby incorporated into this License Agreement by reference. Patents shall also include divisions, continuations (excluding continuations-in-part claiming new subject matter), reissues, re-examinations, substitutes, and extensions of the Patents as they arise.

B. The Licensor's know-how and related rights in regards to the Patents are designated herein together as constituting the Intellectual Property rights concerned by this License Agreement (herein called the "**IP Rights**").

C. The Licensee wishes to acquire from the Licensor and the Licensor agrees to grant to the Licensee the right to use the IP Rights.

D. The Licensee will be a manufacturer of certain products such as but not limited to, protein energy bars, baked goods, meals, protein powders, bottled drinks and others (together or separately, the "**Products**"); all of which will be produced in whole or in part according to the process developed by the Licensor and modified by any such means desirable to the Licensee, and the Licensee will have the ability to sell such Products on a worldwide basis.

E. The Licensor has agreed to grant Licensee the irrevocable right to use the IP Rights under the terms and conditions as set forth in this License Agreement.

NOW THEREFORE in consideration of the premises and the respective covenants, agreements representations, warranties and indemnities of the parties herein contained and for other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged) the parties hereto covenant and agree as follows:

1. DEFINED TERMS

1.1 For the purposes of this Agreement, unless the context otherwise requires, the following terms will have the respective meanings set out below and grammatical variations of such terms will have corresponding meanings:

- (a) "Business Day" means any day which is not a Saturday, Sunday or statutory holiday in the United States and Canada;
-

- (b) "Closing Date" means August 11, 2015, or such other date as the Licensor and the Licensee may mutually determine;
- (c) "IP Rights" has the meaning as ascribed in the whereas Clause B, above.

1.2 Currency. Unless otherwise indicated, all dollar amounts in this License Agreement are expressed in US funds.

1.3 Sections and Headings. The division of this License Agreement into Articles, sections and subsections and the insertion of headings are for convenience of reference only and will not affect the interpretation of this License Agreement. Unless otherwise indicated, any reference in this License Agreement to an Article, section, subsection or Schedule refers to the specified Article, section or subsection of or Schedule to this License Agreement.

1.4 Number, Gender and Persons. In this License Agreement, words importing the singular number only will include the plural and vice versa, words importing gender will include all genders and words importing persons will include individuals, corporations, partnerships, associations, trusts, unincorporated organizations, governmental bodies and other legal or business entities of any kind whatsoever.

1.5 Accounting Principles. Except as otherwise stated, any reference in this License Agreement to generally accepted accounting principles refers to generally accepted accounting principles that have been established in the United States of America, including those approved from time to time by the American Institute of Certified Public Accountants or any successor body thereto.

1.6 Entire Agreement. This License Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether written or oral. There are no conditions, covenants, agreements, representations, warranties or other provisions, express or implied, collateral, statutory or otherwise, relating to the subject matter hereof except as herein provided.

1.7 Time of Essence. Time will be of the essence of this License Agreement.

1.8 Applicable Law. This License Agreement will be construed, interpreted and enforced in accordance with, and the respective rights and obligations of the parties will be governed by, the laws of the Province of British Columbia. All claim demands, disputes, controversies, differences, or misunderstandings between the Parties relating to this Agreement shall be settled by arbitration before one arbitrator to be appointed in accordance with the International Chamber of Commerce, such proceeding to be held in Vancouver in the English language and judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.

1.9 Amendments and Waivers. No amendment or waiver of any provision of this License Agreement will be binding on either party unless consented to in writing by such party. No waiver of any provision of this License Agreement will constitute a waiver of any other provision, nor will any waiver constitute a continuing waiver unless otherwise provided.

2. GRANT OF LICENSE

2.1 The Licensor hereby grants to the Licensee, effective as of the Closing Date and for a period of 35 years, a non-exclusive worldwide license, to unencumbered use of the Licensor's IP Rights for consideration of the License Fee defined in Article 5 hereafter (the "License").

- 2.2 The License permits the Licensee to utilize third-party contractors, consultants, employees and any other relationship the Licensee deems necessary in the production of Products for the benefit of the Licensee.
- 2.3 The License permits the Licensee to sell, assign, rent, lease or otherwise apportion rights to use all or any portion of the IP to as yet unidentified third parties, in as few or many instances as the Licensee in its own evaluation deems desirable, for the benefit of the Licensee.
- 2.2 The Licensee agrees to assist the Licensor in recording this License Agreement with appropriate government authorities where such recording is required by law or regulation or where such recording is permitted or desired by the Licensor.
- 2.3 The Licensor retains full perpetual rights to use the IP Rights for its own business operations.

3. **USE OF LICENSE AND PURCHASE OF PRODUCTS**

- 3.1 The License is non-exclusive to the Licensee worldwide;
- 3.2 The Licensee shall pursue trademark on all the Products produced by the Licensee where applicable;

4. **OWNERSHIP**

- 4.1 Licensee acknowledges and agrees that, as between the parties to this License Agreement and subject to the rights and licenses granted herein, Licensor is, and at all times shall remain, the sole and exclusive owner of all title and interest, throughout the world, in and to all IP Rights, whether made on or behalf of Licensor or Licensee.

5. **LICENSE FEE**

- 5.1 The license fee payable by the Licensee to the Licensor for the License shall consist solely of the following:
 - (a) The Licensee shall pay \$10,000 to the Licensor as a one-time payment in full, such payment to be in cash or in working capital already provided from Licensee to Licensor, at the discretion of the Licensor.

6. **TERMINATION AND EXTENSION**

- 6.1 Except as otherwise provided, this License Agreement shall terminate automatically at the end of the term specified in Section 2.1.
 - 6.2 The License Agreement will be terminated if a bankruptcy proceeding is filed against the Licensee.
-

7. INDEMNIFICATION, REMEDIES, SURVIVAL

7.1 For the purposes of this Section 7 the terms "**Loss**" and "**Losses**" mean any and all demands, claims, actions or causes of action, assessments, losses, damages, liabilities, costs, and expenses, including without limitation, interest, penalties, fines and reasonable attorneys, accountants and other professional fees and expenses, but excluding any indirect, consequential or punitive damages suffered by Licensor or Licensee including damages for lost profits or lost business opportunities.

7.2 Agreement of Licensor to Indemnify

- (a) Licensor will indemnify, defend, and hold harmless, to the full extent of the law, for a period of three years from the termination of the License Agreement, the Licensee and its shareholders from, against, and in respect of any and all Losses asserted against, relating to, imposed upon, or incurred by the Licensee and its shareholders by reason of, resulting from, based upon or arising out of:
 - (i) the breach by Licensor of any representation or warranty of Licensor contained in or made pursuant to this License Agreement, any Licensor document or any certificate or other instrument delivered pursuant to this License Agreement; or
 - (ii) the breach or partial breach by Licensor of any covenant or agreement of Licensor made in or pursuant to this License Agreement, any Licensor document or any certificate or other instrument delivered pursuant to this License Agreement.

7.3 Agreement of Licensee to Indemnify

- (a) Licensee will indemnify, defend, and hold harmless, to the full extent of the law, for a period of two years from the termination of this License Agreement, the Licensor from, against, for, and in respect of any and all Losses asserted against, relating to, imposed upon, or incurred by Licensor by reason of, resulting from, based upon or arising out of:
 - (i) the breach by Licensee of any representation or warranty of Licensee contained in or made pursuant to this License Agreement, any Licensee document or any certificate or other instrument delivered pursuant to this License Agreement; or
 - (ii) the breach or partial breach by Licensee of any covenant or agreement of Licensee made in or pursuant to this Agreement, any Licensee document or any certificate or other instrument delivered pursuant to this License Agreement.

8. REPRESENTATIONS AND WARRANTIES OF THE LICENSOR

8.1 The Licensor represents and warrants to the Licensee, with the intent that the Licensee will rely thereon in entering into this License Agreement and in concluding the transactions contemplated hereby, as follows:

- (a) Licensor warrants that to the best of its knowledge the use of the IP Rights as intended through this License Agreement, does not infringe upon the rights of third parties;
 - (b) Licensor warrants that to the best of its knowledge the IP Rights is valid, maintained and enforceable towards third parties worldwide;
 - (c) the execution and delivery of this License Agreement and the completion of the transactions contemplated hereby have been duly and validly authorized by all necessary limited liability company action on the part of the Licensor, and this License Agreement constitutes a valid and binding obligation of the Licensor enforceable against the Licensor in accordance with its terms; except as enforcement may be limited by bankruptcy, insolvency and other laws affecting the rights of creditors generally and except that equitable remedies may be granted only in the discretion of a court of competent jurisdiction;
-

- (d) except as will be remedied by the consents, approvals, releases, and discharges described in Schedule 2 - Consents attached hereto, neither the execution and delivery of this License Agreement nor the performance of the Licensor's obligations hereunder will:
 - (i) violate or constitute default under any order, decree, judgment, statute, by-law, rule, regulation, or restriction applicable to the Licensor, the IP Rights, or any contract, agreement, instrument, covenant, mortgage, or security, to which the Licensor is a party or which are binding upon the Licensor,
 - (ii) to the knowledge of the Licensor, result in any fees, duties, taxes, assessments, penalties or other amounts becoming due or payable by the Licensee under any sales tax legislation,
 - (iii) give rise to the creation or imposition of any encumbrance on the IP Rights,
 - (iv) violate or constitute default under any license, permit, approval, consent or authorization held by the Licensor, or
 - (v) violate or trigger any liability on behalf of the Licensee pursuant to any legislation governing the licensing of the IP Rights by the Licensor;
 - (e) the Licensor owns and possesses and has good and marketable title to the IP Rights free and clear of all encumbrances of every kind and nature whatsoever;
 - (f) no person other than the Licensee has any written or oral agreement or option or any right or privilege (whether by law, pre-emptive or contractual) capable of becoming an agreement or option for the purchase or acquisition from the Licensor of any of the IP Rights;
 - (g) there are no actions, suits, proceedings, investigations, complaints, orders, directives, or notices of defect or noncompliance by or before any court, governmental or domestic commission, department, board, tribunal, or authority, or administrative, licensing, or regulatory agency, body, or officer issued, pending, or to the best of the Licensor's knowledge threatened against or affecting the Licensor or in respect of the IP Rights;
 - (h) there is no requirement applicable to the Licensor to make any filing with, give any notice to or to obtain any license, permit, certificate, registration, authorization, consent or approval of, any governmental or regulatory authority as a condition to the lawful consummation of the transactions contemplated by this Agreement, except for the filings, notifications, licenses, permits, certificates, registrations, consents and approvals described in Schedule 2 - Consents, or that relate solely to the identity of the Licensee or the nature of any business carried on by the Licensee except for the notifications, consents and approvals described in Schedule 2 - Consents;
-

9. REPRESENTATIONS OF THE LICENSEE

- 9.1 The Licensee represents and warrants to the Licensor as follows, with the intent that the Licensor will rely thereon in entering into this License Agreement and in concluding the transactions contemplated hereby, that:
- (a) the Licensee is a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Nevada and has the power, authority, and capacity to enter into this License Agreement and to carry out its terms;
 - (b) the execution and delivery of this License Agreement and the completion of the transactions contemplated hereby has been duly and validly authorized by all necessary corporate action on the part of the Licensee, and this Agreement constitutes a valid and binding obligation of the Licensee enforceable against the Licensee in accordance with its terms; except as enforcement may be limited by bankruptcy, insolvency and other laws affecting the rights of creditors generally and except that equitable remedies may be granted only in the discretion of a court of competent jurisdiction;
 - (c) there is no requirement for the Licensee to make any filing with, give any notice to or obtain any license, permit, certificate, registration, authorization, consent or approval of, any government or regulatory authority as a condition to the lawful consummation of the transactions contemplated by this License Agreement;
 - (d) neither the execution and delivery of this License Agreement nor the performance of the Licensee's obligations hereunder will violate or constitute a default under the constating documents, by-laws, or articles of the Licensee, any order, decree, judgment, statute, by-law, rule, regulation, or restriction applicable to the Licensee, or any contract, agreement, instrument, covenant, mortgage or security to which the Licensee is a party or which are binding upon the Licensee;
 - (e) there are no actions, suits, proceedings, investigations, complaints, orders, directives, or notices of defect or non-compliance by or before any court, governmental or domestic commission, department, board, tribunal, or authority, or administrative, licensing, or regulatory agency, body, or officer issued, pending, or to the best of the Licensee's knowledge threatened against or affecting the Licensee; and the Licensee is in compliance in all material respects with all applicable laws applicable to Licensee and its business; and
 - (f) The Licensee will use its reasonable best efforts to ensure the commercial success of the Products during the life of this License Agreement.

10. NON MERGER

- 10.1 The representations, warranties, covenants, and agreements of the Licensor contained herein and those contained in the documents and instruments delivered pursuant hereto or in connection herewith will survive the Closing Date and the term of this License Agreement, and notwithstanding the completion of the transactions contemplated hereby, the waiver of any condition contained herein (unless such waiver expressly releases the Licensor of such representation, warranty, covenant, or agreement), or any investigation by the Licensee, same will remain in full force and effect.
- 10.2 The representations, warranties, covenants, and agreements of the Licensee contained herein and those contained in the documents and instruments delivered pursuant hereto or in connection herewith will survive the Closing Date and the term of this License Agreement, and notwithstanding the completion of the transactions contemplated hereby, the waiver of any condition contained herein (unless such waiver expressly releases the Licensee of such representation, warranty, covenant, or agreement), or any investigation by the Licensor, same will remain in full force and effect.
-

11. FURTHER ASSURANCES

11.1 From time to time subsequent to the Closing Date, the parties covenant and agree, at the expense of the requesting party, to promptly execute and deliver all such further documents and instruments and do all such further acts and things as may be required to carry out the full intent and meaning of this Agreement and to effect the transactions contemplated hereby.

12. ASSIGNMENT

12.1 This Agreement may not be assigned by any party hereto without the prior written consent of the other parties hereto.

13. SUCCESSORS AND ASSIGNS

13.1 This Agreement will enure to the benefit of and be binding upon the parties hereto and their respective successors and permitted assigns.

14. COUNTERPARTS

14.1 This Agreement may be executed in several counterparts, each of which will be deemed to be an original and all of which will together constitute one and the same instrument.

15. NOTICES

15.1 Any notice required or permitted to be given under this Agreement will be in writing and may be given by personal service or by prepaid registered mail, and addressed to the proper party or transmitted by electronic facsimile generating proof of receipt of transmission at the address or facsimile number stated below:

(a) if to the Licensor:

Bal Bhullar

Facsimile No.:

(b) if to the Licensee:

Lexaria Corp
Suite 950 - 1130 West Pender Street
Vancouver, BC V6E 4A4

Facsimile No.:

with a copy to:

Macdonald Tuskey
Suite 400 – 570 Granville Street
Vancouver, BC V6C 3P1

Attention: William L. Macdonald

Facsimile No.: +1 (604) 681-4760

or to such other address or facsimile number as any party may specify by notice. Any notice sent by registered mail as aforesaid will be deemed conclusively to have been effectively given on the fifth business day after posting; but if at the time of posting or between the time of posting and the third business day thereafter there is a strike, lockout or other labour disturbance affecting postal service, then such notice will not be effectively given until actually received. Any notice transmitted by electronic facsimile will be deemed conclusively to have been effectively given if evidence of receipt is obtained before 5:00 p.m. (recipient's time) on a Business Day, and otherwise on the Business Day next following the date evidence of receipt of transmission is obtained by the sender.

16. TENDER AND EXTENSIONS

16.1 Tender may be made upon the Licensor or Licensee or upon the solicitors for the Licensor or Licensee and such solicitors are expressly authorized by their respective clients to confirm extensions of the Closing Date.

17. REFERENCE DATE

17.1 This Agreement is dated for reference as of the date first above written, but will become binding as of the date of execution and delivery by all parties hereto and subject to compliance with the terms and conditions hereof, the transfer and possession of the Business Assets will be deemed to take effect as at the close of business on the Closing Date. References herein to the date of the Agreement or to the date hereof shall be deemed to mean the date set forth in the preamble to this Agreement.

IN WITNESS WHEREOF the parties have executed and delivered these presents on the dates indicated below.

POVIVA TEA, LLC

Per: _____
Authorized Signatory

Dated: _____

Per: _____
Authorized Signatory

Dated: _____

LEXARIA CORPORATION

Per: _____
Authorized Signatory

Dated: _____

Per: _____
Authorized Signatory

Dated: _____



EXHIBIT A

U.S. Provisional Patent Application Serial No. 62/010,601 filed June 11, 2014

U.S. Provisional Patent Application Serial No. 62/037,706 filed August 15, 2014

U.S. Provisional Patent Application Serial No. 62/153,835 filed April 28, 2015

U.S. Provisional Patent Application Serial No. 62/161,324 filed May 14, 2015

U.S. Utility Patent Application Serial No. 14/735,844 filed June 10, 2015

PCT Patent Application Serial No. PCT/US15/35128 filed June 10, 2015

Lexaria Introduces NEW ViPova™ Products

Kelowna, BC / August 12, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) is pleased to announce a suite of new ViPova™ products available for purchase immediately. The new products all utilize Lexaria’s patent-pending technology designed to enhance bioavailability.

In addition to the new products listed below, Lexaria is pleased to announce that ViPova™ brand coffee and hot chocolate are expected to be available in September; and that the much-anticipated Lexaria Energy protein bar is expected to be available around the end of September, in two initial flavors. More information on these products will be released as available.

Among the highest selling tea categories in the world are Black, De-Caf, Green, and Earl Gray – and Lexaria is pleased to inform its stakeholders that with today’s announcement, we now offer teas in most of the world’s favored categories. This is an additional important step in delivering the superfood goodness of hemp through popular foods.

The new ViPova™ brand teas that are now available are:

Earl Gray Tea

Rich Bergamot flavored broken orange pekoe and infused hemp oil. The distinctive citrus flavor comes from the oil extracted from the rind of the bergamont orange, a small citrus tree grown mostly in Italy. For those craving something more exotic, try “London Fog” comprised of ViPova™ Earl Gray tea, steamed milk and a touch of vanilla.

Herbal Cherry Black Tea

Fruity, sweet cherry and safflower combined with black tea and hemp oil. With the traditional caffeine content of black tea, this is a bright and flavorful pick-me-up in the morning or mid day. Delicious.

Low-Caf Organic Evening Green Tea

Blended organic green teas and rich hemp oil with a nutty flavor and reddish-gold appearance. Low in caffeine, ViPova™ Evening Green Tea is perfect as a calming, soothing brew in the afternoon and evening, and only ViPova™ brand Evening Green Tea contains hemp oil specially formulated for enhanced absorption.

De-Caf English Breakfast Tea

A smooth, traditional broken orange pekoe modernized with our patent-pending hemp oil infusion. You may have tried orange pekoe before, but nowhere else will you find our patent pending formula. Naturally de-caffeinated, you can enjoy this day and night while experiencing hemp’s superfood qualities.

Herbal Masala Chai Tea

ViPova™ has developed unique spiced tea formulations you simply cannot find anywhere else! A sweet & spicy blend of rooibos, ginger, cinnamon, cardamom, vanilla, and hemp oils. Rooibos contains polyphenols and is high in ascorbic acid. Naturally free of caffeine, this wonderful blend can be enjoyed any time of day or evening.

Herbal Bengal Chai Tea

Our most complex blend of rooibos, pepper, cloves, ginger, cinnamon, cardamom, vanilla and hemp oils. Rooibos is caffeine-free, does contain polyphenols and is naturally high in ascorbic acid. The cinnamon and vanilla make it sweet, but you'll appreciate its spicy side too.

All the teas listed above are in stock now and available for immediate shipping directly to consumers at just \$24 for 8-bag packs, with incentives for larger quantities. Wholesalers are always welcome to make contact to discuss commercial terms. Order at www.vipova.com

The new tea flavors join the existing two tea lines - ViPova™ Starter and ViPova™ Original Yunnan Black – to now offer consumers a total of 8 different ViPova™ tea experiences. ViPova Starter 4-bag tea packs are an entry-level product with our lowest price to the consumer at just \$10.

Lexaria believes the greatly expanded line of tea flavors and recent lower pricing will together combine to offer consumers their most compelling options in the marketplace today, for flavorful foods delivering the goodness of hemp oil compounds. Together with the ever expanding number of online and traditional locations to buy the products, Lexaria believes it is on the cusp of a meaningful increase in sales revenues.

Lexaria also points out the balanced offering of caffeinated and de-caffeinated products. Containing caffeine are the Vipova™ Starter; ViPova™ Original Yunnan; Earl Gray; Herbal Cherry; and Low-caf Evening Green. Free of caffeine are the English Breakfast; Masala Chai; and Bengal Chai.

Separately, Lexaria also announces that it has signed a license agreement with 51%-owned subsidiary PoViva Tea LLC, formalizing and granting Lexaria a 35-year worldwide license to use and re-license the patent-pending technology covered under four different US Provisional Patent Applications, one US Utility Patent Application, and one PCT Patent Application.

Lexaria's technology is designed to allow for higher bioavailability rates for THC and for CBD than is possible without lipophilic enhancement technology. This can allow for lower overall dosing requirements and/or higher effectiveness in active molecule delivery. Lexaria's innovative lipid formulation process is designed to allow the delivery of molecules such as are contained within hemp oil without the harmful side effects of ingestion via smoking, and should be embraced for the benefits to public health.

About Lexaria

Lexaria is a food sciences company focused on the delivery of hemp oil compounds procured from legal, agricultural hemp, through gourmet foods based upon its proprietary infusion technologies. www.lexariaenergy.com

About ViPova™

ViPova™ uses only legal hemp oil extracts, grown from agricultural hemp in locations where it is legal to do so, in ViPova™-branded tea. ViPova™ uses its patent-pending process to infuse concentrated amounts of hemp oil within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova™ has this ground-breaking technology for hemp oil/lipid infusion. www.vipova.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the medical marijuana, hemp oil sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company's needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
